Eli Lilly & Co.: Partnering in Europe: Lilly's Take on the Landscape




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Eli Lilly & Co.: Partnering in Europe: Lilly's Take on the Landscape
Released on: October 01, 2007. © PharmaVentures Ltd
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    In this exclusive interview, live from Geneva, Fintan Walton talks to Andrew Wood, Executive Director, Global External R&D Europe at Eli Lilly & Co.
  • Summary
  • Participants
  • Company
In this exclusive interview, live from Geneva, Fintan Walton talks to Andrew Wood, Executive Director, Global External R&D Europe at Eli Lilly & Co. They start by talking about Andrew’s function within Lilly and the company’s strategy to partner not only within its main areas of therapeutic focus, but also to be open to new opportunities or ‘white space’. They go on to discuss Lilly’s philosophy around R&D, and how current trends in the deal landscape, such as a move towards earlier stage deals and company acquisitions, may affect its partnering activities. Andrew also talks about how the establishment of Lilly’s Alliance Management system has helped the company to be a good and competitive partner. Finally, differences between opportunities in the US and Europe are considered, as well as the challenges facing Andrew and his team going forward.
After qualifying in medicine at Oxford University, Andrew Wood went on to spend a further decade in Oxford in the field of academic medicine, specifically in clinical pharmacology and psychiatry. In 1991, he joined Lilly, where his main focus was drug development, with particular focus on neuroscience. Since joining Lilly, Andrew has led both clinical and preclinical research activities in the UK, Belgium and Japan. In his current role in which he is focused on Europe, Andrew works at the interface between Lilly’s scientists and external innovators in the partnering arena.
Eli Lilly & Co.
Eli Lilly and Company is a global pharmaceutical company. Eli Lilly's global headquarters is located in Indianapolis, Indiana, in the United States. The company was founded in 1876 by a pharmaceutical chemist, Eli Lilly, after whom the company was ultimately named.

Among other specialties, Lilly was the first company to mass-produce penicillin and today is the world's largest manufacturer and distributor of psychiatric medications.